Advanced Proteome Therapeutics Corporation (APC.V)
| Previous Close | 0.1150 |
| Open | 0.1350 |
| Bid | 0.1150 x 0 |
| Ask | 0.1350 x 0 |
| Day's Range | 0.1400 - 0.2100 |
| 52 Week Range | 0.0900 - 0.3500 |
| Volume | |
| Avg. Volume | 21,074 |
| Market Cap | 6.795M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry
[DATELINE]Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), has had its technology featured in a peer-reviewed publication.The manuscript entitled, "Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates" by Sarrett, et al. has been published in the prestigious journal, Bioconjugate Chemistry. Bioconjugate Chemistry is a peer-rev
- Newsfile
Advanced Proteome Therapeutics Receives Issued Patent
Vancouver, British Columbia--(Newsfile Corp. - August 3, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the United States Patent and Trademark Office has issued a patent to its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").On August 2, 2022, APTI was issued U.S. Patent No. 11,400,165 titled 'Composition and method for modifying polypeptides'. The patent covers highly site-selective antibody conjugate c
- Newsfile
Advanced Proteome Therapeutics Receives Notice of Allowance for Patent Claims
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") has received a notice of allowance for patent claims covering key intellectual property.APTI has been informed that the first set of claims from US patent application 16/180,960 have been allowed. These claims cover highly site-selective antibody conju
